Clinicopathologic Features and Survival Analysis of Non-metastatic Breast Cancer Patients in Guatemala

Archives of Breast Cancer

article

Hugo Castro-Salguero¹  Luis García Aceituno²  Alba Kihn³  Raúl Jiménez²  Allan Ramos-Esquivel⁴ 

[1] Grupo Médico Ángeles, Guatemala City;Social Security Institute of Guatemala;Nacional Institute of Cancer of Guatemala;School of Medicine, University of Costa Rica

关键词: Brest cancer;    Guatemala;    survival;   

DOI  :  10.32768/abc.202073111-118

学科分类：社会科学、人文和艺术（综合）

来源: Kaviani Breast Disease Institute

【 摘 要 】

Background: Breast cancer (BC) is a leading cause of cancer related death worldwide. Unfortunately, data concerning clinicopathologic features of this malignancy in non-developed countries is scarce. This study aims to characterize a cohort of Guatemalan female patients with non-metastatic BC and to determine risk factors for overall survival (OS). Methods: We retrieved data on consecutive patients from the Instituto Guatemalteco de Seguridad Social that were treated from 2008 to 2014. Clinical features and long-term outcomes were retrieved from medical records. Univariate and multivariate Cox regression analyses were conducted to identify variables associated with OS. Results: 954 BC patients were identified during the time frame. A total of 436 women (46%) were younger than 50 years old. BC molecular subtypes categorized 537 patients (56.3%) with luminal A disease, 186 (19.5%) patients with triple negative tumors, 153 cases (16.1%) with HER-2 enriched tumors, and 78 patients (8.2%) with luminal B tumors. Clinical stage at presentation was stage I: 4.7% (n=45); stage II: 48.1% (n=459), and stage III: 47.2% (n=450). The overall 5-year survival rate was 75.2% (95% Confidence Interval: 72.0–78.3). In the multivariate analysis clinical stage, triple negative tumors and HER2 enriched tumors were independently associated with poor survival.Conclusion: The majority of patients with non-metastatic BC are diagnosed with advanced disease and many of them are younger than 50 years old. OS in this cohort of Guatemalan patients is lower than that reported in developed countries.

【 授权许可】

CC BY-NC